INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
INVO Bioscience, Inc. (Nasdaq: INVO) filed this Current Report on Form 8-K on April 11, 2024, regarding events occurring on April 5, 2024. The filing details the entry into a Material Definitive Agreement and the subsequent unregistered sale of equity securities to raise capital for working capital and general corporate purposes.
Key Financial Metrics and Transaction Details
This filing does not report standard operating metrics such as revenue, profit, or cash flow for a fiscal period. Instead, it outlines a specific financing transaction with the following terms:
- Total Purchase Price: $250,000 paid by FirstFire Global Opportunities Fund, LLC.
- Securities Issued:
- Promissory Note: $275,000 principal amount, 12% annual interest (first year interest of $33,000 guaranteed and fully earned at issuance).
- First Warrant: Right to purchase 229,167 shares at $1.20 per share.
- Second Warrant: Right to purchase 500,000 shares at $0.01 per share (exercisable only upon an Event of Default).
- Commitment Shares: 50,000 shares of Common Stock issued immediately.
- Transaction Costs: $25,000 cash fee paid to placement agent Carter, Terry, & Company, Inc.
- Debt Maturity: 12 months from the issue date.
Material Changes and Covenants
The transaction introduces significant debt obligations and potential equity dilution subject to specific covenants:
- Prepayment Penalty: The Company may prepay the Note at any time by paying 110% of the principal plus accrued interest.
- Future Proceeds Clause: If the Company raises more than $1,500,000 from any source (or $1,000,000 from a public offering), the Buyer has the right to require immediate repayment of the Note using proceeds above these thresholds.
- Operational Restrictions: The Company is restricted from declaring dividends, making certain investments, selling assets outside the ordinary course, or entering into affiliate transactions until the Note is repaid.
- Stockholder Approval: The Company must seek stockholder approval within nine months to issue shares exceeding the 19.99% "Exchange Cap" (523,344 shares) without violating Nasdaq Listing Rule 5635(d).
Outlook, Risks, and Contingencies
Management commentary is limited to the transaction mechanics. Key risks and contingencies identified include:
- Default Risk: Events of default include failure to pay principal/interest, breach of covenants, bankruptcy, or failure to comply with Exchange Act reporting. Default triggers immediate repayment and activates the Second Warrant.
- Dilution Risk: The transaction includes a "Returnable Warrant" (Second Warrant) that becomes exercisable at a nominal price ($0.01) only if a default occurs, creating a significant contingent dilution risk for existing shareholders.
- Liquidity Constraints: The covenants restrict the Company's ability to access capital markets or distribute cash to shareholders while the Note is outstanding.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the $275,000 debt obligation plus the $33,000 guaranteed interest.
- Confirm the timeline for the stockholder meeting required to approve share issuances exceeding the 19.99% cap.
- Assess the likelihood of the "Future Proceeds" clause being triggered by any planned fundraising activities.
- Review the Company's compliance history with Exchange Act reporting requirements to evaluate default risk.
- Calculate the potential dilution impact if the Second Warrant (500,000 shares at $0.01) were to be exercised upon a default event.